These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Inotropic drugs in treatment of heart failure--advantages and adverse reactions]. Witkowska M Pol Tyg Lek; 1992 Oct 5-12; 47(40-41):936-40. PubMed ID: 1300581 [TBL] [Abstract][Full Text] [Related]
3. [Positive inotropic substances. Possible use in heart failure in the aged]. Michel D Fortschr Med; 1991 Aug; 109(25):496-9. PubMed ID: 1937336 [TBL] [Abstract][Full Text] [Related]
4. Milrinone: a positive inotropic vasodilator. Colucci WS; Jaski BE; Fifer MA; Wright RF; Braunwald E Trans Assoc Am Physicians; 1984; 97():124-33. PubMed ID: 6535335 [No Abstract] [Full Text] [Related]
5. Is the efficacy of positive inotropic drugs limited to symptomatic improvement? Baumann G; Felix SB Herz; 1991 Sep; 16 Spec No 1():304-13. PubMed ID: 1820297 [TBL] [Abstract][Full Text] [Related]
6. New positive inotropic drugs in the treatment of congestive heart failure. Kennedy GT Prog Cardiovasc Nurs; 1987; 2(3):100-4. PubMed ID: 2959954 [No Abstract] [Full Text] [Related]
7. [Pre-, intra- and postoperative heart failure: diagnosis, treatment strategies and control of effectiveness]. Kromer EP Klin Anasthesiol Intensivther; 1995; 47():61-75. PubMed ID: 7715180 [No Abstract] [Full Text] [Related]
8. [New aspects for therapy of chronic heart failure with positive inotropic substances]. Erdmann E Verh Dtsch Ges Inn Med; 1991; 97():178-84. PubMed ID: 1808882 [No Abstract] [Full Text] [Related]
9. New positive inotropic agents. Jafri SM; Bristol JA Henry Ford Hosp Med J; 1986; 34(3):188-92. PubMed ID: 3542907 [No Abstract] [Full Text] [Related]
10. Istaroxime, a novel luso-inotropic agent for the treatment of acute heart failure. Wehrens XH Curr Opin Investig Drugs; 2007 Sep; 8(9):769-77. PubMed ID: 17729189 [TBL] [Abstract][Full Text] [Related]
11. [New inotropic agents in the treatment of congestive heart failure]. Hutton I; McKillop J; Clark R; Martin W; Tweddel A Ter Arkh; 1982; 54(11):98-101. PubMed ID: 7157176 [No Abstract] [Full Text] [Related]
12. [Therapy of heart failure. I. Definition, pathophysiology, therapy of acute heart failure]. Schwinger RH; Erdmann E Fortschr Med; 1997 Jun; 115(16):30-4. PubMed ID: 9280746 [TBL] [Abstract][Full Text] [Related]
15. [Pathomechanisms of heart failure]. Urbaszek W Z Arztl Fortbild (Jena); 1993; 87(8 Suppl 4):1-4. PubMed ID: 8105608 [No Abstract] [Full Text] [Related]
16. [Current role of non-digitalis inotropic agents in acute and chronic treatment of heart failure]. Dei Cas L; Nodari S; Raddino R; Metra M; Pelà G; Nardi M Cardiologia; 1994 Mar; 39(3):209-15. PubMed ID: 8039201 [No Abstract] [Full Text] [Related]
17. The future of inotropic drugs in clinical practice. Smith TW Eur Heart J; 1982 Dec; 3 Suppl D():149-56. PubMed ID: 6130948 [No Abstract] [Full Text] [Related]
19. Inotropic agents. Gerry JL; Pappas ND; Glancy DL J La State Med Soc; 1982; 134(2):51-2. PubMed ID: 7108341 [No Abstract] [Full Text] [Related]
20. [Acute hemodynamic and clinical effects of a new inotropic agent, levosimendan, in patients with severe heart failure]. Porcu M; Orrù P Ital Heart J Suppl; 2001 Feb; 2(2):205-6. PubMed ID: 11255888 [No Abstract] [Full Text] [Related] [Next] [New Search]